NRAS and rectal carcinoma: Mutually exclusive KRAS and NRAS mutations were identified, with recurrent activating mutations observed commonly in colon and rectal carcinoma (COAD/READ) (30%, 5%, and 5% for KRAS (Gly 12), KRAS (Gly 13), and NRAS (Gln 61), respectively) [35].